Title & Introduction

  • Paper Title: Safety and Efficacy of Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Post-Traumatic Stress Disorder: An Overview of Systematic Reviews and Meta-Analyses
  • Published In: Australian & New Zealand Journal of Psychiatry
  • Publish Date: 2025
  • Authors: Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani, Brooke Blakeley, Christopher G. Davey, J. Simon Bell
  • Objective: To critically evaluate published and unpublished systematic reviews and meta-analyses on the safety and efficacy of MDMA-assisted psychotherapy for PTSD.
  • Importance: MDMA-assisted psychotherapy (MDMA-AP) has shown promise in treating PTSD, but concerns regarding the quality of evidence and safety outcomes necessitate a thorough review of existing literature.

Summary & Takeaways

Key Takeaway:
MDMA-assisted psychotherapy improves PTSD symptoms and increases response and remission rates, but the evidence is rated as low to very low certainty due to methodological limitations and potential biases.

Practical Application:
Clinicians and policymakers should consider MDMA-AP as a potential PTSD treatment, but further research is needed to strengthen evidence quality and ensure long-term safety.

Key Background Information

  • Context: PTSD affects millions globally and is particularly prevalent among military veterans. Traditional treatments are often ineffective for many patients, necessitating alternative approaches.
  • Hypothesis: MDMA-AP enhances PTSD symptom relief by facilitating emotional processing and reducing fear responses in a therapeutic setting.

Methodology

  • Study Design: Overview of systematic reviews and meta-analyses.
  • Participants: 353 individuals across 20 primary studies included in 14 systematic reviews.
  • Intervention/Exposure: MDMA-assisted psychotherapy (50–125 mg MDMA, 1–3 sessions, sometimes with supplemental doses).
  • Controls: Active placebo (25–40 mg MDMA) or inactive placebo combined with psychotherapy.
  • Duration: Literature reviewed up to May 9, 2024.

Key Findings

Primary Outcomes:

  • MDMA-AP improved PTSD symptoms with a standardized mean difference (SMD) of 0.8–1.3 compared to psychotherapy alone.
  • Response rates were significantly higher in MDMA-AP groups (relative risk [RR]: 1.3–3.5).
  • Remission rates were also improved (RR: 2.3–2.9).
  • Long-term follow-up (2–74 months) suggested a sustained reduction in PTSD symptoms (SMD: 0.8–1.1).
  • MDMA-AP showed a reduction in depressive symptoms (mean difference in Beck Depression Inventory: -10.8 to -11.1).
  • Some studies reported enhanced daily functioning (Sheehan Disability Scale reduction of -1.5).

Secondary Outcomes:

  • Safety Concerns: Moderate evidence indicated increased transient adverse events (odds ratio [OR]: 1.7–3.5).
  • Long-Term Safety: Limited data on prolonged adverse effects; 2–4% of participants reported adverse events after 12 months.
  • Placebo Effects: Functional unblinding was a concern, as many participants could distinguish between MDMA and placebo.
  • Bias in Reporting: Discrepancies were noted between published adverse event data and clinical trial registries.

Interpretation & Implications

  • Conclusion: MDMA-AP demonstrates efficacy in treating PTSD, but methodological issues and low certainty of evidence highlight the need for further well-designed trials.
  • Implications: Regulatory agencies should ensure rigorous trial designs before considering widespread clinical use. Continued post-approval monitoring is necessary to assess long-term safety.
  • Limitations: High risk of bias in systematic reviews, lack of long-term controlled studies, and reliance on spontaneous adverse event reporting.

Researchers & Publication

  • Researchers: Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani, Brooke Blakeley, Christopher G. Davey, J. Simon Bell
  • Publication Name: Australian & New Zealand Journal of Psychiatry
  • Study URL: https://doi.org/10.1177/00048674251315642
Share this post